NICE Technology Appraisals of Oncology Treatments

This white paper discusses the technology appraisals (TAs) of oncology treatments conducted by the National Institute for Health and Care Excellence (NICE). It outlines NICE's role in providing evidence-based best practices for cancer treatment access in England and Wales, emphasizing the impact of these appraisals on healthcare technology assessments globally. The document details the types of recommendations made by NICE, including those for treatments recommended for use, optimized recommendations, and those designated for research use only. It also reviews the economic modeling approaches used in these appraisals, highlighting the predominance of cost-utility analysis. The paper presents a two-year review of 66 TAs, focusing on specific cancer indications and the relationship between modeling approaches and recommendation outcomes. Additionally, it discusses the introduction of a severity modifier in NICE's assessment criteria, which aims to better address treatments for severe and life-limiting conditions, thus influencing cost-effectiveness thresholds. Overall, the paper serves as a comprehensive guide for manufacturers navigating the NICE appraisal process.